Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

New clues to the cause of Alzheimer’s disease

By R&D Editors | June 30, 2011

New clues to the cause of Alzheimer’s disease

Researchers at the Sahlgrenska Academy, University of Gothenburg, have identified a series of  novel proteins in human cerebrospinal fluid. The proteins, which carry specific sugar molecules, are found in greater concentrations in patients with dementia caused by Alzheimer’s disease than in patients with dementia caused by other diseases. This gives hope for new forms of treatment in the future.

Göran Larson is a professor at the Sahlgrenska Academy and one of the authors of the article published in the revered journal Proceedings of the National Academy of Sciences USA (PNAS).

“When it comes to the link to Alzheimer’s, we’re thinking first and foremost of the possibilities to use these molecules as markers for an early and reliable diagnosis, but also, of course, of what role these molecules may play in the development and course of the disease.”

These new molecules give researchers another way of thinking of the mechanisms behind Alzheimer’s disease. Larson and his research team are already working with other researchers at the Sahlgrenska Academy and Chalmers University of Technology to develop new analytical techniques for measuring the concentrations of these molecules in cerebrospinal fluid. The aim is to try to make the analyses more sensitive, as well as simpler, cheaper and more accessible so that they can be used as routine clinical assays when investigating dementia.

“Dementia is a major and growing problem not just for healthcare but for society as a whole since more people are getting older and older, and the single largest risk factor for Alzheimer’s is just that – old age,” says Larson. “There isn’t currently any effective pharmaceutical treatment for Alzheimer’s, but if this discovery can contribute to an early diagnosis then medicines that slow the progression of the disease can be tried before the dementia gets too severe.

“If we can link the formation of these molecules to the disease mechanisms behind Alzheimer’s, then there’s hope that we can also develop new drugs that can affect the course of this serious disease.”

ALZHEIMER’S DISEASE

With more than 100,000 people affected in Sweden, Alzheimer’s is one of the most common diseases of our society. Caused by changes in the brain tissue, the disease predominantly affects the memory and often leads to an earlier death. Alzheimer’s disease results in not only considerable suffering for patients and their families, but also in huge costs to society.

SOURCE

Related Articles Read More >

Why IBM predicts quantum advantage within two years
Aardvark AI forecasts rival supercomputer simulations while using over 99.9% less compute
This week in AI research: Latest Insilico Medicine drug enters the clinic, a $0.55/M token model R1 rivals OpenAI’s $60 flagship, and more
How the startup ALAFIA Supercomputers is deploying on-prem AI for medical research and clinical care
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE